Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancer
Ofra Novoplansky(Ben-Gurion University of the Negev), Moshe Elkabets(Ben-Gurion University of the Negev)
Cited by 33
Related Papers
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
|International Journal of Cancer|2019|31
IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer
|Cancers|2021|13
Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
|Journal of Experimental & Clinical Cancer Research|2024|6
The AP-1 complex regulates AXL expression and determines sensitivity to PI3Kα inhibition in esophagus and head and neck squamous cell carcinoma
|bioRxiv (Cold Spring Harbor Laboratory)|2018|2
TRAF3 Suppression Encourages B Cell Recruitment and Prolongs Survival of Microbiome-Intact Mice with Ovarian Cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1